ID Source | ID |
---|---|
PubMed CID | 12306667 |
SCHEMBL ID | 4998375 |
MeSH ID | M0043602 |
Synonym |
---|
antheridiol |
3,22,23-trihydroxy-7-oxostigmasta-5,24(28)-dien-29-oic acid gamma-lactone |
unii-b1u1mf1dn9 |
22263-79-2 |
b1u1mf1dn9 , |
antheridiol [mi] |
stigmasta-5,24(28)-dien-29-oic acid, 3,22,23-trihydroxy-7-oxo-, .gamma.-lactone, (3.beta.,22s,23r)- |
SCHEMBL4998375 |
Q27274261 |
(2r)-2-[(1s,2s)-1-hydroxy-2-[(3s,8s,9s,10r,13r,14s,17r)-3-hydroxy-10,13-dimethyl-7-oxo-1,2,3,4,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]propyl]-3-propan-2-yl-2h-furan-5-one |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 7 (63.64) | 18.7374 |
1990's | 3 (27.27) | 18.2507 |
2000's | 1 (9.09) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.89) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 11 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |